Ensysce Biosciences (ENSC) Interest Expenses (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Interest Expenses of -$27433.0 for Q4 2025, down 1118.68% year-over-year from $2693.0 in Q4 2024, and down 530.73% quarter-over-quarter from $6369.0 in Q3 2025.
Ensysce Biosciences (ENSC) Interest Expenses (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Interest Expenses for 7 consecutive years, with -$27433.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Interest Expenses fell 1118.68% year-over-year to -$27433.0; the TTM figure through Dec 2025 stood at -$14048.0 (down 101.1% YoY), while the FY2025 annual figure was $2.0 million, up 56.06% from the prior year.
- Interest Expenses declined to -$27433.0 in Q4 2025 per ENSC's latest filing, from $6369.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $53.7 million in Q2 2021 and bottomed at -$27433.0 in Q4 2025.
- Historically, Interest Expenses has averaged $3.1 million across 5 years, with a median of $7649.0 in 2023.
- Annual changes were most pronounced in 2024 — Interest Expenses soared 83271.08% — and 2025, when it sank 1118.68%.
- Ensysce Biosciences' Interest Expenses stood at $97481.0 in 2021, then advanced by 5.31% to $102661.0 in 2022, then plunged by 94.57% to $5570.0 in 2023, then plunged by 51.65% to $2693.0 in 2024, then tumbled by 1118.68% to -$27433.0 in 2025.
- Business Quant data shows ENSC's Interest Expenses at -$27433.0 in Q4 2025, $6369.0 in Q3 2025, and $3160.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | -992.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27,433.00 |
| Dec 31, 2025 | -27,433.00 |
| Sep 30, 2025 | 6,369.00 |
| Sep 30, 2025 | 6,369.00 |
| Jun 30, 2025 | 3,160.00 |
| Jun 30, 2025 | 3,160.00 |
| Mar 31, 2025 | 3,856.00 |
| Mar 31, 2025 | 3,856.00 |
| Dec 31, 2024 | 2,693.00 |
| Dec 31, 2024 | 2,693.00 |
| Sep 30, 2024 | 4,063.00 |
| Sep 30, 2024 | 4,063.00 |
| Jun 30, 2024 | 27,563.00 |
| Jun 30, 2024 | 27,563.00 |
| Mar 31, 2024 | 1.25 Mn |
| Mar 31, 2024 | 1.25 Mn |
| Dec 31, 2023 | 5,570.00 |
| Dec 31, 2023 | 5,570.00 |
| Sep 30, 2023 | 7,649.00 |
| Sep 30, 2023 | 7,649.00 |